Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
128 Results for "
bone resorption inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (128)
128 Results for "bone resorption inhibitor" in MCE Product Catalog:
10
10 Publications Verification
Cat. No.: HY-B0631
CAS No.: 66376-36-1
Target:
Research Areas:
Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research .
10
10 Publications Verification
Synonyms: Alendronic acid monosodium salt
Target:
Research Areas:
Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research .
6
Target:
Research Areas:
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
5
Target:
Research Areas:
Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
5
5 Cited Publications
Cat. No.: HY-A0020
CAS No.: 104121-92-8
Synonyms: ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
Research Areas:
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
5
Target:
Research Areas:
Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .
5
4
4 Cited Publications
Cat. No.: HY-N0257
CAS No.: 110623-72-8
3
Target:
Research Areas:
3
3 Cited Publications
Synonyms: Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
Target:
Research Areas:
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
3
3 Cited Publications
Cat. No.: HY-N2532
CAS No.: 22055-22-7
Category:
Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Plants Infection Monophenols Phenols Phenylpropanoids Berberidaceae Disease Research Fields Inflammation/Immunology
Target:
3
3 Cited Publications
Target:
Research Areas:
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
3
3
Target:
Research Areas:
2
Research Areas:
Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
2
Research Areas:
Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
2
2 Cited Publications
Target:
Research Areas:
TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
2
Target:
Research Areas:
Et-29 (NRD167) is a selective SIRT5 inhibitor. Et-29 increases the levels of total protein succinylation and citrate synthase succinylation in cells. Et-29 reduces serum CTX-I levels and blocks Ferroptosis by downregulating the SIRT5/ACSL4/LPCAT3/ALOX15 axis and restoring antioxidant defense. Et-29 decreases bone resorption and improves trabecular bone mass and microarchitecture. Et-29 is applicable for research related to osteoporosis and hepatocellular carcinoma .
2
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
1
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
